Inhibrx Ebit from 2010 to 2025
| INBX Stock | USD 13.34 0.01 0.07% |
EBIT | First Reported 2018-03-31 | Previous Quarter -43.9 M | Current Value -47.9 M | Quarterly Volatility 371.6 M |
Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx's main balance sheet or income statement drivers, such as Interest Expense of 10.6 M, Minority Interest of 0.0 or Tax Provision of 1.9 K, as well as many indicators such as Price To Sales Ratio of 1.2 K, Dividend Yield of 0.0021 or PTB Ratio of 1.79. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules.
Inhibrx | Ebit |
Latest Inhibrx's Ebit Growth Pattern
Below is the plot of the Ebit of Inhibrx over the last few years. It is Inhibrx's EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx's overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Inhibrx Ebit Regression Statistics
| Arithmetic Mean | 173,461,516 | |
| Geometric Mean | 56,971,024 | |
| Coefficient Of Variation | 354.71 | |
| Mean Deviation | 392,532,527 | |
| Median | (19,704,000) | |
| Standard Deviation | 615,283,113 | |
| Sample Variance | 378573.3T | |
| Range | 2B | |
| R-Value | 0.52 | |
| Mean Square Error | 296000.7T | |
| R-Squared | 0.27 | |
| Significance | 0.04 | |
| Slope | 67,182,570 | |
| Total Sum of Squares | 5678599.6T |
Inhibrx Ebit History
Other Fundumenentals of Inhibrx
About Inhibrx Financial Statements
Inhibrx investors use historical fundamental indicators, such as Inhibrx's Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | 1.7 B | 1.8 B | |
| EBITDA | 1.7 B | 1.8 B | |
| Ebt Per Ebit | (5.09) | (4.84) | |
| Ebit Per Revenue | -1.7 K | -1.6 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.